Search the Newsreel

Haverty Furniture Companies (NYSE:HVT) Upgraded at Wall Street Zen

Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)?

Biohaven Ltd. reported narrowing losses in Q2 2026, with a net loss of US$137.31 million, and appointed AI-focused investor John Yetimoglu to its Board. Despite these developments, the company still faces significant financial risk due to zero revenue, heavy ongoing losses, and a short …

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron's cemiplimab (Libtayo) in patients with solid tumors. …

Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven

Woodline Partners LP has reported a beneficial ownership of 5.1% in Biohaven Ltd., amounting to 7,660,280 Common Shares. This ownership grants Woodline Partners sole voting and dispositive power over these shares, which are held through Woodline Master Fund LP and Woodline Spire Master Fund …

BHAV Acquisition Corp Completes $100M IPO, Deposits Funds in Trust

BHAV Acquisition Corp (NASDAQ: BHAVU, BHAV, BHAVR) completed its $100 million IPO on March 20, 2026, depositing the full proceeds into a trust account, which held $100,979,443 as of June 30, 2026. The blank-check company, which has no operations, must complete a business combination …

BHAV Acquisition Corp 2Q 2026: Net income $701K, EPS $0.05— 10-Q Summary

BHAV Acquisition Corp reported a net income of $701,173 for the second quarter of 2026 and $713,174 for the six months ended June 30, 2026. The company recorded diluted earnings per share of $0.05 for the quarter and $0.08 for the six-month period. BHAV …

BHAV Acquisition Corp (BHAV) earns $0.7M on $101M SPAC trust in Q2

Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN

Renaissance Technologies LLC has acquired a new position in Biohaven Ltd. (NYSE:BHVN), purchasing 160,952 shares valued at approximately $1.36 million. This move comes as institutional investors collectively own 88.78% of Biohaven, with several major funds significantly increasing their stakes. Despite missing quarterly EPS expectations, …

Sri Havisha Q1 Results: Board approves unaudited financials

Havells India Shares Gain 2.04%, Among Top Gainers on Nifty Midcap 150

Raghav Productivity Enhancers Ltd. Share Price at 52-Week

Kochav Defense Acquisition Corp. Class A Ordinary Shares (NASDAQ: KCHV) Stock Price, News & Analysis

This article provides stock price, news, and analysis for Kochav Defense Acquisition Corp. Class A Ordinary Shares (NASDAQ: KCHV). It includes real-time stock data, fundamental metrics, and outlines available financial reports and research services provided by Kalkine, which are primarily sourced from EOD Historical …

Kochav Defense Acquisition Corp. Q2 2026: Net income $2.13M, EPS $0.06— 10-Q Summary

Kochav Defense (KCHV) posts $4.2M income but flags going concern risk

Sadbhav Engineering June-Quarter Consol Net Profit 156.7 Million Rupees

Sadbhav Engineering Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Madhav Marble Q1 Results: Standalone profit falls 30% YoY to ₹11.27 lakh

Sri Havisha Hospitality & Infrastructure reports standalone net loss of Rs 1.82 crore in the June 2026 quarter

Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

Bank of America Securities has reiterated a Buy rating on Biohaven Ltd. (BHVN) with a price target of $11.00, despite the stock closing higher at $14.54. Analyst Dina Ramadane, who covers the Healthcare sector, has a 61.54% success rate on her recommendations. The broader …

Havilah Resources (ASX:HAV): Large Copper-Gold Resource Base Awaits Development Pathway

Sadbhav Infrastructure clears Q1 results, reshapes board and subsidiary asset framework

Sadbhav Infrastructure Board Clears Q1 Results, Restructuring Moves Across Key Road Assets

Sadbhav Infrastructure Board Clears Q1 Results, Auditor Exit and Subsidiary Asset Moves

Sadbhav Infrastructure Board Clears Q1 Results, Auditor Exit and Key Asset Moves Ahead of AGM

Sadbhav Infrastructure Clears Q1 FY27 Results, Restructures Subsidiaries and Auditor Line-Up

Sadbhav Infrastructure posts ₹175.94M profit in Q1FY27

Sadbhav Infrastructure Q1 Results: Standalone profit at INR 175.94M vs loss YoY

Haverty Furniture (HVT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:00 p.m. ET CALL PARTICIPANTS Assistant Vice President of Financial Reporting and Investor Relations - Tiffany Hinkle President and Chief Executive Officer - Steven Burdette Executive Vice President and Chief Financial Officer - …

Biohaven Pharma stock price target raised to $23 by RBC Capital

RBC Capital has raised its price target for Biohaven Pharma (NYSE:BHVN) to $23 from $22, maintaining an Outperform rating, following the company's second-quarter 2026 earnings report. The firm highlights potential opportunities in troriluzole and degrader data, estimating a more than $4 billion market by …

Vaibhav Global reports 50% profit surge in Q1FY27, declares interim dividend

Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity

Biohaven Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company, reported a net loss of $267.8 million for the first half of 2026, primarily due to $204.6 million in research and development expenses. The company maintains liquidity with $267.9 million in cash, cash equivalents, and marketable …

Manoj Vaibhav Gems 'N' Jewellers standalone net profit rises 33.90% in the June 2026 quarter

Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Biohaven (NYSE:BHVN) announced its quarterly earnings, reporting a loss of $0.78 per share, which missed analysts' consensus estimates by $0.02. Following the announcement, shares of Biohaven dropped 0.5% to $14.58. Despite the earnings miss, analyst sentiment for Biohaven remains a "Moderate Buy" with an …